logo-loader
RNS
EMV Capital

EMV Capital PLC - Portfolio Update and Presentation

RNS Number : 9658L
EMV Capital PLC
13 July 2026
 

For announcement on Reach: 07.00 a.m., 13 July 2026

 

EMV Capital plc

(EMV Capital or EMVC or the Company or the Group)

 

Portfolio Update

 

As part of its ongoing investor engagement programme, EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, is pleased to announce that it will host a virtual Meet the Portfolio event on 27 July 2026 at 2.00 p.m. The session will provide investors with greater insight into two of its portfolio companies, AMR Bio and ProAxsis.

 

Virtual Meet the Portfolio - AMR Bio and ProAxsis

 

The online event will take place via the Investor Meet Company platform and will be hosted by Dr Ilian Iliev, CEO of EMV Capital plc, who will be joined by:

 

·      Nigel Brooksby, Executive Chair of AMR Bio, a clinical phase biotechnology company dedicated to infection prevention, who will provide an update on the progress of its XF-73 asset as it advances towards Phase 3 clinical trials, and

 

·      Dr Louise Ryan Murphy, Managing Director of ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights, who will provide an update on the Company's repositioning and recent progress, including its growth in the COPD market through a clinical study with Imperial College London.

 

This presentation is open to all interested parties. Anyone can sign up for free and join the live presentation via:

 

https://www.investormeetcompany.com/emv-capital-plc/register-investor

 

Those who already follow the Company on the Investor Meet Company platform will automatically be invited.

 

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 26 July 2026 at 9:00 a.m., or at any time during the live presentation.

 

In accordance with UK Market Abuse Regulation (UK MAR), no inside information will be disclosed during the event.

-ends-

 

For more information, please contact:

 

EMV Capital plc

via Rosewood

Ilian Iliev, CEO

 

 

 

Panmure Liberum Limited (NOMAD and Broker)

+44 (0)20 7886 2500

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

 

Rupert Dearden (Corporate Broking)

 

 

 

Rosewood (Financial PR)

+44 (0)20 7653 8702

John West / Llewellyn Angus / Lily Pearce


 

About EMV Capital plc (EMVC)

 

EMV Capital plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, EMV Capital invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

 

·      capital-efficient investments through Group balance sheet;

·      fund management of the Evergreen EIS and Martlet Capital Funds;

·      syndicated investments leveraging its network of third-party investors.

 

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

 

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

 

www.emvcapital.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPURPMUPQGQU
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Metals One, Critical Mineral Resources, Ariana Resources, IXICO, EMV...

Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF) is targeting uranium recovery from historic mine waste in Colorado's Uravan Belt with zero capex exposure, thanks to its partnership with DISA Technologies.  Gamma data is due by end of May and assay results by Q3, with a potential revenue stream...

on 05/23/2026

4 min read